# EDGAR Filing Document

**Accession Number:** 0001527613
**File Stem:** 0001493152-26-009024
**Filing Date:** 2026-3
**Character Count:** 111909
**Document Hash:** 56e1e64330b5d861d753fc6c46e25a59
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-009024.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001493152-26-009024

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CIMG Inc.
- **CENTRAL INDEX KEY:** 0001527613
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-MISCELLANEOUS RETAIL [5900]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 383849791
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39338
- **FILM NUMBER:** 26727551

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ROOM R2, FTY D, 16/F, KIN GA IND. BLDG.
- **STREET 2:** 9 SAN ON STREET, TUEN MUN
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** (760) 295-2408

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ROOM R2, FTY D, 16/F, KIN GA IND. BLDG.
- **STREET 2:** 9 SAN ON STREET, TUEN MUN
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NuZee, Inc.
- **DATE OF NAME CHANGE:** 20130604

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Havana Furnishings Inc.
- **DATE OF NAME CHANGE:** 20110815

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Havanna Furnishings Inc.
- **DATE OF NAME CHANGE:** 20110809

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended December 31, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission File Number 001-39338**

**CIMG Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **38-3849791** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**Room R2, FTY D, 16/F, Kin Ga Industrial Building, 9 San On Street, Tuen Mun, Hong Kong**

(Address of principal executive offices)

**+ 852 70106695**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common Stock, $0.00001 par value IMG | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
| Emerging growth company ☐ |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 5, 2026, there were 15,483,547 shares of the registrant's Common Stock outstanding.

CIMG INC.

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2025

---

| | | |
|:---|:---|:---|
| **PART I.** | [FINANCIAL INFORMATION](#m_001) | 3 |
| Item 1. | [Financial Statements](#m_001) | 3 |
|  | [Consolidated Balance Sheets (unaudited)](#F_001) | 3 |
|  | [Consolidated Statements of Operations (unaudited)](#F_002) | 4 |
|  | [Consolidated Statements of Comprehensive Income Loss (unaudited)](#F_003) | 5 |
|  | [Consolidated Statements of Changes in Stockholders' Equity (unaudited)](#F_004) | 6 |
|  | [Consolidated Statements of Cash Flows (unaudited)](#F_005) | 7 |
|  | [Notes to Consolidated Financial Statements (unaudited)](#F_006) | 8 |
| Item 2. | [Quantitative and Qualitative Disclosures About Market Risk](#m_002) | 30 |
| Item 3. | [Controls and Procedures](#m_004) | 30 |
| **PART II.** | [OTHER INFORMATION](#m_005) | 31 |
| Item 1. | [Legal Proceedings](#m_006) | 31 |
| Item 1A. | [Risk Factors](#m_007) | 31 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#m_008) | 31 |
| Item 3. | [Defaults Upon Senior Securities](#m_009) | 31 |
| Item 4. | [Mine Safety Disclosures](#m_010) | 31 |
| Item 5. | [Other Information](#m_011) | 31 |
| Item 6. | [Exhibits](#m_012) | 31 |
|  | [SIGNATURES](#m_013) | 33 |

---

**Cautionary Note Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements, including, without limitation, in the sections captioned "Risk Factors" and elsewhere. Any and all statements contained in this Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as "may," "might," "would," "should," "could," "project," "target," "seek," "estimate," "predict," "potential," "strategy," "anticipate," "attempt," "develop," "plan," "help," "believe," "continue," "intend," "expect," "future" and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Report may include, without limitation, statements regarding:

● our
 plans to obtain funding for our operations, including the funds required for technological development, product production, and product
 commercialization, as well as the funds necessary to ensure our continuous operation;

● our
 expectation that our existing capital resources will be sufficient to fund our operations for at least the next twelve months and
 our expectation to need additional capital to fund our planned operations beyond that;

● the
 accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

● our
 expectations regarding our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;

● the
 impact to our business, including any supply chain interruptions, resulting from changes in general economic, business and political
 conditions, including changes in the financial markets and macroeconomic conditions resulting from a pandemic;

● the
 market size and growth trend of our products;

● our
 ability to compete with those companies that sell similar products or offer similar services;

● our
 ability to successfully achieve the anticipated results of strategic transactions;

● our
 expectations for future sales performance;

● our
 reliance on raw material suppliers or product manufacturers is to enable us to better produce our products and offer a wider variety
 of products to our customers.;

● regulatory
 developments in the U.S. and other countries;

● our
 ability to retain key management, sales, and marketing personnel;

● the
 scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology;

● our
 ability to develop and maintain our corporate infrastructure, including our internal control over financial reporting;

● the
 outcome of pending, threatened, or future litigation;

● our
 financial performance; and

● our
 use of the net proceeds from our recent offerings.

The forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Any forward-looking statements in this Report reflect our current views with respect to future events or our future financial performance and involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may influence or contribute to the inaccuracy of the forward-looking statements, or cause actual results to differ materially from current expectations, include, among other things, those listed under "Item 1A—Risk Factors" in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 13, 2026, and in our other reports filed with the SEC. Given these uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update the forward-looking statements contained in this Report to reflect any new information or future events or circumstances, or otherwise, except as required by law.

**Item 1. Financial Statements**

**CIMG Inc.**

**CONSOLIDATED BALANCE SHEETS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **September 30,**<br>**2025** |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalent | $45356 | $137287 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 1385960 | 55258 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 157 | 11893318 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1850651 | 4948022 |
| &nbsp;&nbsp;&nbsp;Other Receivables - Related Parties | 208714 | 92457 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | **3490838** | **17126342** |
| **Non-current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 1988 | 2200 |
| &nbsp;&nbsp;&nbsp;Right-of-use asset - operating lease | 12927 | 20340 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 1396 | 2201 |
| &nbsp;&nbsp;&nbsp;Digital assets | 63978821 | 57024465 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total non-current assets** | **63995132** | **57049206** |
| **Total assets** | $**67485970** | $**74175548** |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $2864751 | $1464144 |
| &nbsp;&nbsp;&nbsp;Short term loan | 452764 | 447164 |
| &nbsp;&nbsp;&nbsp;Current portion of lease liability - operating lease | 6445 | 13346 |
| &nbsp;&nbsp;&nbsp;Convertible note-related party |  | 1838041 |
| &nbsp;&nbsp;&nbsp;Other payables-related party | 612939 | 211475 |
| &nbsp;&nbsp;&nbsp;Advance Received | 780649 | 105653 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 3941470 | 22250590 |
| &nbsp;&nbsp;&nbsp;Tax payable | 2394591 | 1314686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | **11053609** | **27645099** |
| **Total liabilities** | $**11051607** | $**27645099** |
| **Stockholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;15,483,382 and 9,825,704 shares of Common Stock issued and outstanding as of December 31, 2025 and September 30, 2025, respectively\* | 156 | 99 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 161961688 | 132531653 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (106705592) | (87228118) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 416217 | 431598 |
| **Total shareholders' equity of the Company** | **55672469** | **45735232** |
| &nbsp;&nbsp;&nbsp;Non-controlling interests | 759892 | 795217 |
| **Total stockholders' equity** | **56432361** | **46530449** |
| **Total liabilities and stockholders' equity** | $**67485970** | $**74175548** |

---

\* On December 5, 2025, the Company effected a 1-for-20 reverse stock split (the "Reverse Stock Split") of its issued and outstanding shares of Common Stock, par value $0.00001 per share. The Reverse Stock Split has reduced the number of shares of Common Stock as of September 30, 2025 from 196,514,084 shares to 9,825,704 shares, and corresponding retroactive adjustments have been made to all the data for the listed period.

**The accompanying notes are an integral part of these consolidated financial statements.**

**CIMG Inc.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br>**December 31, 2025** | **Three Months Ended**<br>**December 31, 2024** |
| Revenues, net | $15768796 | $22853 |
| Cost of sales | (15679685) | (7374) |
| &nbsp;&nbsp;&nbsp;**Gross profit** | **89111** | **15479** |
| Operating expenses | (2046352) | (1517758) |
| **Loss from operations** | **(1957241)** | **(1502279)** |
| Fair value variation | (17502596) |  |
| Other income | 74115 | 9047 |
| Loss from equity method investment |  |  |
| Other expense | (125150) | (43017) |
| Interest expense, net | - | - |
| **Net loss from continuing operations** | **(19510872)** | **(1536249)** |
| Income Tax | - | - |
| **Net loss** | $**(19510872)** | **(1536249)** |
| **Non-controlling interest** | **(33398)** | **-** |
| **Net loss attributable to CIMG Inc.** | **(19477474)** | **(1536249)** |
| Basic and diluted loss per common share | (1.43) | (0.17) |
| Basic and diluted weighted average number of Common Stock outstanding | 13601997 | 8982676 |

---

**The accompanying notes are an integral part of these consolidated financial statements.**

**CIMG Inc.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br>**December 31, 2025** | **Three Months Ended**<br>**December 31,** **2024** |
| **Net loss attributable to CIMG Inc.** | $**(19477474)** | $**(1536249)** |
| &nbsp;&nbsp;&nbsp;Foreign currency translation to CIMG Inc. | (15381) | (192038) |
| **Total other comprehensive income net of tax to CIMG Inc.** | **(15381)** | **(192038)** |
| **Comprehensive loss to CIMG Inc.** | $**(19492855)** | $**(1728287)** |

---

**The accompanying notes are an integral part of these consolidated financial statements.**

**CIMG Inc.**

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(UNAUDITED)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | | | | | |
|  | Shares<sup>\*</sup> | Amount | Additional <br> paid-in<br>capital | Accumulated<br>deficit | Accumulated <br> Other <br> Comprehensive<br>income | Non-controlling<br>interests |<br>Total |
| **Balance September 30, 2025** | **9825704** | $**99** | $**132531653** | $**(87228118)** | $**431598** | $**795217** | $**46530449** |
| Common Stock issued for cash | 416667 | 4 | 1999996 |  |  |  | 2000000 |
| Common Stock compensation | 363970 | 4 | 1163972 |  |  |  | 1163976 |
| Issued private placement | 3595000 | 36 | 16177464 |  |  |  | 16177500 |
| Issued warrants | 1282051 | 13 | 10088603 |  |  |  | 10088616 |
| Other comprehensive income |  |  |  |  | (15381) | (1927) | (17308) |
| Net loss | - | - | - | (19477474) | - | (33398) | (19510872) |
| **Balance December 31, 2025** | **15483392** | $**156** | $**161961688** | $**(106705592)** | $**416217** | $**759892** | $**56432361** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares\*** | **Amount** | **Additional<br> paid-in**<br>**capital** | **Accumulated**<br>**deficit** | **Accumulated<br> Other<br> Comprehensive**<br>**income** |<br>**Total** |
| **Balance September 30, 2024** | **248912** | $**2** | $**81260653** | $**(82344722)** | $**433399** | $**(650668)** |
| Common Stock issued for cash | 69841 | 1 | 1382843 |  |  | 1382844 |
| Common Stock compensation | 40000 | 1 | 523679 |  |  | 523680 |
| Issued private placement | 175438 | 2 | 1999998 |  |  | 2000000 |
| Issued warrants | 2799 | 1 |  |  |  | 1 |
| Other comprehensive income |  |  |  |  | (192038) | (192038) |
| Net loss | - | - | - | (1536249) | - | (1536249) |
| **Balance December 31, 2024** | **536990** | $**6** | $**85167173** | $**(83880971)** | $**241361** | $**1527570** |

---

\* Corresponding retroactive adjustments have been made to all the data for the listed period to reflect the Reverse Stock Split.

**The accompanying notes are an integral part of these consolidated financial statements.**

**CIMG Inc.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br>**December 31, 2025** | **Three Months Ended**<br>**December 31, 2024** |
| **Operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(19510872) | $(1536249) |
| **Adjustments to reconcile net loss to net cash used in operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Fair value variation | 17502596 |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 1017 | 7771 |
| &nbsp;&nbsp;&nbsp;Noncash lease expense | 7413 | 41349 |
| &nbsp;&nbsp;&nbsp;Common Stock compensation | 1163976 | 523680 |
| **Change in operating assets and liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (1330702) |  |
| &nbsp;&nbsp;&nbsp;Inventories | 11893161 | (60272) |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 3097370 | 91487 |
| &nbsp;&nbsp;&nbsp;Other receivables - related party | (116257) |  |
| &nbsp;&nbsp;&nbsp;Digital assets | (24456951) |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | 1400607 | (420136) |
| &nbsp;&nbsp;&nbsp;Other payables-related party | 401464 |  |
| &nbsp;&nbsp;&nbsp;Accrued Interest | 5600 |  |
| &nbsp;&nbsp;&nbsp;Lease liability - operating lease | (6901) | (42659) |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 1420781 | 56248 |
| &nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | **(8527698)** | **(1338781)** |
| **Financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Repayment from loans |  | (1486996) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible notes |  | 678308 |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of Common Stock, exercise of stock options | 8453075 | 2000000 |
| &nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **8453075** | **1191312** |
| Effect of foreign exchange on cash | (17308) | (192038) |
| Net change in cash | (91931) | (339507) |
| Cash, beginning of period | 137287 | 464222 |
| Cash, end of period | $45356 | 124715 |
| **Supplemental disclosure of cash flow information:** |  |  |
| Cash paid for interest |  | $- |
| Cash paid for taxes |  | $- |
| **Noncash investing and financing activities:** |  |  |
| Deferred Stock Offering cost accrued ROU assets and liabilities added during the period | $- | 32092 |

---

**The accompanying notes are an integral part of these consolidated financial statements.**

**CIMG Inc.**

**Notes to Consolidated Financial Statements** (unaudited)

**December 31, 2025**

**1. ORGANIZATION**

CIMG Inc. (the "Company") is incorporated in the State of Nevada and has been listed on the Nasdaq Stock Market since June 2020. The Company was formerly known as Nuzee, Inc., with the ticker symbol "NUZE", and changed its corporate name and ticker symbol to "CIMG Inc." and "IMG", respectively, in October 2024.

The Company previously focused on specialty coffee products and related technologies. It is currently expanding its sales and distribution channels in Asia to encompass a broader range of consumer food and beverage products, supported by its online sales platform that incorporates a natural language search function.

CIMG Inc., its Hong Kong subsidiary DZR Tech Limited, and its U.S. subsidiary Wewin Technology LLC may transfer cash to the Company's PRC subsidiaries through capital contributions and intercompany loans, subject to applicable regulatory requirements.

On January 13, 2025, the Company established a wholly owned subsidiary in Singapore, CIMG PTE. LTD. ("Singapore CIMG").

On March 10, 2025, Zhongyan Shangyue Technology Co., Ltd. ("Beijing Zhongyan"), a wholly owned subsidiary of the Company, acquired 51% of the equity interests in Shanghai Huomao Cultural Development Co., Ltd. ("Shanghai Huomao"). Shanghai Huomao holds 90% of the equity interests in Guizhou Zhutai Huomao Liquor Industry Co., Ltd. ("Zhutai").

On March 21, 2025, Beijing Zhongyan established a wholly owned subsidiary, Henan Zhongyan Shangyue Technology Co., Ltd. ("Henan Zhongyan").

On March 27, 2025, Beijing Zhongyan entered into a business cooperation intent agreement with Xilin Online (Beijing) E-commerce Co., Ltd. ("Beijing Xilin"), pursuant to which certain shareholders of Beijing Xilin intended to transfer an aggregate of 51% of their equity interests to Beijing Zhongyan. The Company completed the acquisition of Beijing Xilin on March 31, 2025, following completion of the required business registration procedures in China.

On April 22, 2025, the Company completed the acquisition of Shanghai Huomao, together with the related business registration updates.

On August 1, 2025, Beijing Zhongyan entered into a business cooperation intent agreement with Shenzhen Zhimeng Qiyang Technology Co., Ltd. ("Zhimeng"), pursuant to which certain shareholders of Zhimeng agreed to transfer an aggregate of 51% of their equity interests to Beijing Zhongyan. The transfer was completed on August 1, 2025, and the related business registration change was approved on September 29, 2025.

On September 3, 2025, Beijing Zhongyan established a wholly owned subsidiary, Beijing Zhongyan Shangyue Holdings Co., Ltd. ("Beijing Shangyue").

On September 16, 2025, Henan Zhongyan established a wholly owned subsidiary, Henan Nuanyou Agricultural Science and Technology Co., Ltd..

On September 23, 2025, DZR Tech Limited acquired Braincon Limited ("Braincon HK") and its subsidiary, Beijing Xin Miao Shi Dai Technology Development Co., Ltd. ("Beijing Xinmiao"). DZR Tech Limited holds 100% of the equity interests in Braincon Limited.

On December 8, 2025, Beijing Zhongyan established a wholly owned subsidiary, Shenzhen Zhixi Yunjie Technology Co., Ltd. ("Zhixi Yunjie").

On February 4, 2026, Beijing Xinmiao established a wholly-owned subsidiary, Foshan Dingyue Technology Co., Ltd.

On February 5, 2026, Beijing Zhongyan established a wholly-owned subsidiary, Foshan Lintai Technology Co., Ltd.

**2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**2.1 BASIS OF PREPARATION**

The summary of significant accounting policies presented below is designed to assist in understanding the Company's financial statements. Such financial statements and accompanying notes are the representations of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects and have been consistently applied in preparing the accompanying financial statements.

**2.2 PRINCIPLES OF CONSOLIDATION**

The Company's consolidated financial statements include the financial statements of the Company and entities controlled by the Company and its subsidiaries.

A subsidiary is an entity in which the Company, directly or indirectly, controls more than one half of the voting powers; or has the power to appoint or remove the majority of the members of the board of directors; or to cast a majority of votes at the meeting of directors; or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.

All intercompany transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

**2.3 NON-CONTROLLING INTERESTS**

For the Company's non-whole-owned subsidiaries, a non-controlling interest is recognized to reflect the portion of equity that is not attributable, directly or indirectly, to the Company. Non-controlling interests are classified as a separate line item in the equity section of the Company's consolidated balance sheets and have been separately disclosed in the Company's consolidated statements of operations and comprehensive (loss)/income to distinguish the interests from that of the Company.

**2.4 EARNINGS PER SHARE**

 

Basic earnings per common share are calculated by dividing net income or loss attributable to common shareholders by the weighted-average number of shares of Common Stock outstanding during the period.

Diluted earnings per common share reflect the potential dilution that could occur if securities or other contracts to issue Common Stock, such as stock options, warrants, or equity awards, were exercised or vested and resulted in the issuance of Common Stock that would share in the earnings of the Company. Potentially dilutive securities are excluded from the calculation of diluted earnings per share when their effect would be anti-dilutive.

On December 5, 2025, the Company effected a 1-for-20 reverse stock split of its issued and outstanding shares of Common Stock, par value $0.00001 per share. All share and per-share amounts presented in the consolidated financial statements and accompanying notes have been retrospectively adjusted to reflect the Reverse Stock Split.

**2.5 GOING CONCERN AND CAPITAL CONSIDERATIONS**

The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2025, the Company had cash of $45,356 and negative working capital of $7,562,771. The Company expects that it will need to raise additional capital immediately to continue funding its operations. There can be no assurance that such financing will be available on acceptable terms, or at all.

As of December 31, 2025, the Company held 730 Bitcoin with a carrying amount of $63,978,821. While these digital assets may be monetized, their value is subject to significant market volatility, and they do not represent committed or assured sources of financing.

These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Management's plans to address these conditions include raising additional equity or debt financing and executing its revised business strategy. However, as of the issuance date of these consolidated financial statements, management's plans have not alleviated the substantial doubt about the Company's ability to continue as a going concern.

The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty.

**2.6 USE OF ESTIMATE*S***

In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Areas where management uses subjective judgment include, but are not limited to valuation of inventories and inventory impairment, fair value measurements of digital assets, assessment of goodwill impairment, allowance for credit losses, recoverability of deferred tax assets, and the recognition and measurement of revenue. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.

**2.7 FAIR VALUE MEASUREMENTS**

 ****

The Company applies the fair value measurement guidance in ASC 820, Fair Value Measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used in valuation techniques and requires disclosures of fair value measurements by hierarchy level.

The fair value hierarchy prioritizes quoted prices in active markets for identical assets or liabilities (Level 1) as the highest priority and unobservable inputs (Level 3) as the lowest priority. Valuation techniques used to measure fair value include the market approach, the income approach, and the cost approach.

The classification of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The three levels of the fair value hierarchy are as follows:

Level 1 — Quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 — Unobservable inputs that reflect the Company's own assumptions.

The Company measures certain assets and liabilities at fair value on both a recurring and non-recurring basis, including digital assets and financial instruments with embedded features, when applicable. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses, other payables, convertible notes and other current liabilities approximate their fair values due to the short-term maturities of these instruments.

**2.8 CASH AND CASH EQUIVALENTS**

The Company considers cash on hand and demand deposits to be cash. Highly liquid investments with original maturities of three months or less at the date of purchase are considered cash equivalents, provided such investments are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value. The Company did not hold any cash equivalents as of December 31, 2025 and 2024.

**2.9 ACCOUNTS RECEIVABLES, NET**

 

Accounts receivables are recorded at invoiced amounts and are evaluated periodically for collectability. The Company estimates an allowance for credit losses based on historical loss experience, the creditworthiness of customers, known and inherent risks in the receivable portfolio, and current economic conditions. Accounts receivables are written off against the allowance for credit losses when they are deemed uncollectible.

**2.10 INVENTORIES, NET**

Inventories, consisting primarily of raw materials and finished goods held for production and sale, are stated at the lower of cost or net realizable value. Inventory cost is determined using the weighted-average cost method. The Company reviews inventory levels on a quarterly basis and records inventory valuation allowances or write-downs, as necessary, to reflect net realizable value based on factors such as inventory aging, historical and forecasted demand, and market conditions.

**2.11 FOREIGN CURRENCY TRANSLATION**

The financial position and results of operations of each of the Company's foreign subsidiaries are measured using the foreign subsidiary's local currency as the functional currency. Revenues and expenses of each such subsidiary have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of stockholders' equity, unless there is a sale or complete liquidation of the underlying foreign investment.

Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.

**2.12 REVENUE RECOGNITION**

The Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.

The Company primarily generates revenue from the trading and sale of goods. Revenue from product revenue is recognized when the Company satisfies its performance obligation by transferring control of the goods to the customer, which generally occurs upon delivery, when title and risk of loss pass to the customer.

For its product trading activities, the Company acts as the principal, as it controls the goods prior to transfer to the customer, bears inventory risk, and has discretion in establishing pricing. Accordingly, product revenue is recognized on a gross basis.

For service arrangements, the Company evaluates whether it controls the services prior to transfer to the customer. When the Company is determined to be the principal, service revenue is also recognized on a gross basis.

**2.13 RETURN AND EXCHANGE POLICY**

 

All products are inspected and securely packaged prior to shipment to help ensure that customers receive products in satisfactory condition. Customers may return products if they are not satisfied, in which case the Company will provide an exchange or refund of the purchase price, net of shipping charges. Return policies for wholesale customers vary in accordance with the terms of their respective agreements.

Under certain customer agreements, the Company provides chargebacks, pursuant to which the Company reimburses customers for a portion of the costs incurred to advertise and promote the Company's products. The Company estimates and accrues such chargebacks based on contractual terms and historical experience. Chargebacks and returns, when applicable, are recorded as reductions of revenue and reflected in net sales.

For the three months ended December 31, 2025 and 2024, the Company did not record any material sales allowances related to estimated product returns or chargebacks.

**2.14 COST RECOGNITION**

The Company is engaged in the trading of goods and the provision of related services, with its cost of revenue covering products under the Maca Product Series, the Homology of Medicine and Food Series, and the Computing Power Product Series.

For the Maca Product Series, which consists of plant-based products, the Company operates a trading model whereby it procures Maca raw materials and engages third-party processors for production. Costs recognized for this product series primarily include the purchase cost of Maca raw materials, packaging costs, freight and logistics costs, and other directly attributable processing-related expenses.

For the Homology of Medicine and Food Series, the Company operates as a trading intermediary, and the cost of revenue primarily comprises the procurement cost of finished goods purchased from third-party suppliers.

For the Computing Power Product Series, the Company provides technical services supported by the procurement of equipment and development services. The cost of revenue mainly consists of technical development service fees and equipment purchase costs incurred in connection with the delivery of such services.

**2.15 PROPERTY AND EQUIPMENT, NET**

 

Property and equipment are stated at cost and depreciated over their estimated useful lives, with accumulated depreciation and impairment losses recorded as reductions of carrying amounts. Depreciation is computed using the straight-line method over the following estimated useful lives:

- Office equipment: 3 years <br> - Machinery and other equipment: 5 years

**2.16 LONG LIVED ASSETS**

The Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicated that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and a current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances.

**2.17 INTANGIBLE ASSETS**

Intangible assets with finite useful lives that are acquired are carried at cost less accumulated amortization and accumulated impairment losses. Amortization expense is recognized on a straight-line basis over the estimated useful lives of the intangible assets. The estimated useful lives and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. The Company have finite useful life intangible assets related to acquired tradename and software.

**2.18 DIGITAL ASSETS**

The Company's digital assets consist solely of Bitcoin. Digital assets are initially recorded at cost and subsequently remeasured at fair value in accordance with ASU 2023-08. Changes in fair value are recognized in earnings each reporting period.

The fair value of Bitcoin is determined using quoted prices in active markets on Binance, which the Company has determined to be its principal market. Fair value measurements of digital assets are classified within Level 1 of the fair value hierarchy. Changes in fair value are recognized in the consolidated statements of operations within "Fair value variation"

The Company applies the first-in, first-out (FIFO) method to determine the cost basis of digital assets disposed of, if any.

**2.19 INCOME TAXES**

In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company also follows the guidance related to accounting for income tax uncertainties. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.

**2.20 RELATED PARTIES**

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

**2.21 STOCK BASED COMPENSATION**

 

We account for share-based awards issued to employees in accordance with Accounting Standards Codification (ASC) 718, "Compensation-Stock Compensation." Accordingly, employee share-based payment compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period, which is normally the vesting period. Share-based compensation to directors is treated in the same manner as share-based compensation to employees, regardless of whether the directors are also employees. In June 2018, the FASB issued ASU 2018-07 which simplifies several aspects of the accounting for non-employee transactions by stipulating that the existing accounting guidance for share-based payments to employees (accounted for under ASC Topic 718, "Compensation-Stock Compensation") will also apply to non-employee share-based transactions (accounted for under ASC Topic 505, "Equity"). The Company implemented ASU 2018-07 on October 1, 2019 and the impact of the implementation was not material to the financial statements.

During the year, the Company issued an aggregate of 50,000 shares of Common Stock under the 2024 Equity Incentive Plan, consisting of 40,000 shares issued on December 24, 2024 and 10,000 shares issued on April 22, 2025. These amounts reflect the impact of the 1-for-20 reverse stock split, under which 1,000,000 shares issued prior to the stock split were retroactively adjusted to 50,000 shares.

**2.22 COMPREHENSIVE INCOME/LOSS**

Comprehensive income/loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, all items that are required to be recognized under current accounting standards as components of comprehensive income/loss are required to be reported in a financial statement that is presented with the same prominence as other financial statements. The Company's current component of other comprehensive income/loss pertains to foreign currency translation adjustments.

**3. CONCENTRATION AND RISKS**

**3.1 FOREIGN CURRENCY EXCHANGE RATE RISK**

The Company's operating transactions are mainly denominated in RMB. RMB is not freely convertible into foreign currencies. The value of the RMB is subject to changes by the central government policies and to international economic and political developments. In the PRC, certain foreign exchange transactions are required by law to be transacted only through authorized financial institutions at exchange rates set by the People's Bank of China (the "PBOC"). Remittances in currencies other than RMB by the Company in the PRC must be processed through PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documents in order to effect the remittances. As of December 31, 2025 and 2024, the Company's cash and cash equivalents denominated in RMB were RMB 212,146 (approximately $30,235), and RMB 536 (approximately $73), respectively, accounting for 66.66% and 0.06% of the Company's total cash and cash equivalents.

 **3.2 CONCENTRATION OF CREDIT RISK**

The Company's credit risk arises primarily from cash and cash equivalents, accounts receivable, other receivables from related parties, and other receivables included in prepaid expenses and other current assets. The carrying amounts of these financial instruments represent the Company's maximum exposure to credit risk.

As of December 31, 2025, 70% of the Company's cash and cash equivalents were held by major financial institutions located in China and Hongkong, the remaining 30% was held by financial institutions located in the United States. The Company believes that these financial institutions located in China, Hongkong and the United States of high credit quality. Accounts at each institution in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000. As of December 31, 2025, the Company had no cash balances at financial institutions in the United States in excess of the Federal Deposit Insurance Corporation limit.

Accounts receivable and other receivables are generally unsecured and arise in the ordinary course of business. Credit risk associated with these balances is mitigated through customer credit evaluations, ongoing monitoring of outstanding receivable balances, and the recognition of an allowance for expected credit losses based on historical experience, current conditions, and reasonable and supportable forecasts.

**3.3 CONCENTRATION OF CUSTOMERS AND SUPPLIERS**

 

For the three months ended December 31, 2025 and 2024, revenue was primarily derived from major customers disclosed below.

Three months ended December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Customer Name | Sales <br> Amount | % of Total Revenue | Accounts Receivable Amount | % of Total Accounts Receivable |
| Customer ZNF | $11981591 | 75.98% | – |  |
| Customer ZHXY | $1176519 | 7.46% | – |  |

---

Three months ended December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Customer Name | Sales <br> Amount | % of Total<br> Revenue | Accounts<br> Receivable<br> Amount | % of Total<br> Accounts<br> Receivable |
| Customer LXM | $13524 | 59% | $– |  |

---

For the three months ended December 31, 2025 and 2024, inventory purchases, including purchases related to the Company's trading of goods, were primarily made from the major suppliers disclosed below.

Three months ended December 31, 2025:

---

| | | |
|:---|:---|:---|
| Supplier Name | Purchases <br> Amount | % of Total <br> Purchases |
| Supplier TTY | $1080346 | 29.21% |
| Supplier ACJN | 766343 | 20.72% |
| Supplier SCNY | 397944 | 10.76% |
| Supplier YFHYL | 382027 | 10.33% |

---

Three months ended December 31, 2024:

---

| | | |
|:---|:---|:---|
| Supplier Name | Purchases <br> Amount | % of Total <br> Purchases |
| Supplier YKYM | $2058300 | 100% |

---

**4. NOTES TO THE CONSOLIDATED IN FINANCIAL STATEMENTS**

**4.1 ACCOUNTS RECEIVABLE, NET**

 

As of December 31, 2025, the Company had gross accounts receivable of $1,385,960.

As of September 30, 2025, the Company's accounts receivable totaled $55,258, net of an allowance for credit losses of $2,107.

---

| | | |
|:---|:---|:---|
|  | December 31, <br> 2025 | September 30, <br> 2025 |
| Accounts receivable | $1385960 | $57365 |
| Less: allowance for credit losses | - | (2107) |
| **Accounts receivable, net** | **1385960** | **55258** |

---

**4.2 INVENTORIES, NET**

 

Inventories, net consisted of the following:

---

| | | |
|:---|:---|:---|
|  | December 31, <br>2025 | September 30, <br> 2025 |
| Raw materials | $- | $12799608 |
| Finished goods | 157 | 154 |
| **Total inventories, gross** | **157** | **12799762** |
| Less: inventory write-down | - | (906444) |
| **Inventories, net** | **157** | **11893318** |

---

**4.3 PREPAID EXPENSES AND OTHER CURRENT ASSETS**

Prepaid expenses and other current assets as of December 31, 2025 and September 30, 2025 were comprised of the following:

---

| | | |
|:---|:---|:---|
|  | December 31, <br> 2025 | September 30, <br> 2025 |
| Prepaid expenses | $291445 | $197217 |
| Prepaid tax<sup>(1)</sup> | 1286205 |  |
| Advances to suppliers<sup>(2)</sup> | 1458569 |  |
| Deferred equity issuance cost<sup>(3)</sup> | 1797500 |  |
| Other current assets | 114303 | 185431 |
| **Total** | **4948022** | **382648** |

---

(1) Prepaid
 tax represents input value-added tax ("VAT") paid in advance for which the related VAT invoices had not yet been received
 as of the reporting date. Subsequent to period end, the Company received a portion of the outstanding invoices, and management expects
 to obtain the remaining invoices within six months. Accordingly, management believes the prepaid tax balance is fully recoverable.

(2) Advances
 to suppliers totaled $1,458,569, of which $1,404,745 related to a prepayment made to Daren (Beijing) Biomedical Technology Co., Ltd.
 for the procurement of inventory pursuant to a purchase agreement entered into during the year. Subsequent to September 30, 2025,
 the purchase agreement was mutually terminated, and the supplier refunded the full prepayment amount of $1,404,745 to the Company
 in November 2025. As of the date of these financial statements, no amounts remained outstanding related to this advance.

(3) On
 July 1, 2025, the Company entered into a consulting agreement providing for total professional fees of $5.5 million in connection
 with the Company's August 25, 2025 private placement financing of 500 bitcoins (aggregate consideration of $55,000,000). The
 consulting fee was payable in up to 220,000,000 shares of Common Stock. At the transaction date, the Company did not have sufficient
 authorized shares to issue the full 220,000,000 shares. Accordingly, 148,100,000 shares were issued on a pro-rate basis using the
 Company's available authorized shares. The remaining 71,900,000 shares were subject to shareholder approval and an amendment
 to the Company's Articles of Incorporation to increase the authorized share capital. As of September 30, 2025, $1,797,500 of
 the total $5.5 million consulting fee, representing the portion attributable to the 71,900,000 shares not yet issued and therefore
 had not been settled in equity. Accordingly, this amount was recorded as other current assets – deferred equity issuance costs.

**4.4 PROPERTY AND EQUIPMENT, NET**

 

Property and equipment consisted of the following as of December 31, 2025 and September 30, 2025:

---

| | | |
|:---|:---|:---|
|  | December 31, <br> 2025 | September 30, <br> 2025 |
| Machinery & Equipment | $30910 | $30910 |
| Vehicles | - | - |
| **Gross property and equipment** | **30910** | **30910** |
| Less: accumulated depreciation | (28922) | (28710) |
| Less: reclassification to assets held for sale |  |  |
| Less: disposal of property and equipment | - | - |
| **Net property and equipment** | **1988** | **2200** |

---

**4.5 LEASES**

In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, *Leases* (Topic 842), which requires lessees to recognize right-of-use ("ROU") assets and lease liabilities for most lease arrangements. The Company adopted ASC 842 effective October 1, 2019.

The Company evaluates lease arrangements on a quarterly basis to determine whether such arrangements meet the definition of a lease and whether recognition of ROU assets and lease liabilities is required. The Company elected the short-term lease practical expedient for leases with a term of 12 months or less and no purchase option.

**4.5.1 LEASES WITH RECOGNISED ROU ASSETS AND LEASE LIABILITIES**

<u>Vista, California – Office and Manufacturing Space</u>

In May 2022, the Company renewed its office and manufacturing space lease in Vista, California, extending the lease term through September 30, 2025 (the prior lease was scheduled to expire on January 31, 2023). The lease provides for a monthly base rent of $8,451, plus common area maintenance charges. In connection with the renewal, the Company also leased an additional 1,796 square feet at a monthly base rent of $2,514 through March 31, 2025.

<u>Tuen Mun, Hong Kong – Office Space</u>

The Company leases office space on San On Street, Tuen Mun, Hong Kong, under a lease term from December 18, 2024 to December 17, 2026, at a monthly rent of RMB 4,167 (approximately $594). As this lease represents a continuation and renewal of an existing lease and the combined non-cancellable term exceeds 12 months, the Company recognized right-of-use asset and lease liabilities for the lease as a single arrangement.

<u>Beijing, China – Office Space</u>

Effective February 28, 2025, the Company entered into a lease for office space located at Room 303, 3rd Floor, Hongsheng Building, Beijing, China. The lease requires monthly rental payments of RMB 16,425 (approximately $2,301) and expires on March 31, 2026. As the lease term exceeds 12 months, the Company recognized right-of-use asset and lease liabilities related to this lease as of September 30, 2025.

<u>Delray Beach, Florida – Principal Office</u>

Effective September 1, 2024, the Company entered into a lease for its principal office space located at 16097 Poppyseed Circle, Unit 1904, Delray Beach, Florida 33484, for a monthly rent of $3,500. The lease term extended through August 31, 2025, and the lease was not renewed upon expiration.

**4.5.2 SHORT TERM LEASES**

<u>Boca Raton, Florida – Office Space</u>

Effective October 10, 2025, the Company entered into a lease for office space located at 9127 Long Lake Palm Drive, Boca Raton, Florida 33496, with monthly rental payments of $2,500 through October 11, 2026. Because the lease term is 12 months or less, the Company elected the short-term lease practical expedient and, accordingly, did not recognize a right-of-use asset or lease liability related to this lease.

<u>Henan, China – Office Space</u>

The Company leases office space in Henan, China, with annual lease payments of approximately RMB 98,280 (approximately $13,804), payable in monthly installments of RMB 8,190 (approximately $1,150). The lease expires on August 14, 2026. Because the remaining lease term as of September 30, 2025 was less than 12 months, the Company elected the short-term lease practical expedient and did not recognize a right-of-use asset or lease liability related to this lease.

As of December 31, 2025, the Company's operating leases had a weighted-average remaining lease term of one year and a weighted-average discount rate of 3%. Other information related to the Company's operating leases is as follows:

---

| | |
|:---|:---|
| **Right-of-Use Assets** | **Amount** |
| ROU asset – September 30, 2025 | $20340 |
| ROU assets added during the year |  |
| Amortization during the period | (7413) |
| ROU asset – December 31, 2025 | $12927 |

---

---

| | |
|:---|:---|
| **Lease Liabilities** | **Amount** |
| Lease liability – September 30, 2025 | $13346 |
| Lease liability added during the year |  |
| Reduction during the period | (6901) |
| Lease liability – December 31, 2025 | $6445 |

---

---

| | |
|:---|:---|
| **Lease Liabilities by Maturity** | **Amount** |
| Lease Liability – Short-Term | $3502 |
| Lease Liability – Long-Term | 7101 |
| Lease Liability – Total | $10603 |

---

The following table summarizes the Company's operating lease cost, short-term lease cost, and related cash flow information for the year ended December 31, 2025:

---

| | |
|:---|:---|
| Operating lease expenses | $7413 |
| Short-term lease expenses | 3502 |
| Cash paid for amounts included in the measurement of lease liabilities | 7101 |
| Lease amortization | 7413 |
| Interest portion | 108 |

---

**4.6 INTANGIBLE ASSETS, NET**

The following table summarizes the Company's intangible assets as of December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
| Software | 33016 | (31620) | 1396 |
| **Total** | **33016** | **(31620)** | **1396** |

---

The following table summarizes the Company's intangible assets as of September 30, 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
| &nbsp;&nbsp;Trademarks | $140000 | $(140000) | $- |
| &nbsp;&nbsp;Software | 33016 | (30815) | 2201 |
| &nbsp;&nbsp;**Total** | **173016** | **(170815)** | **2201** |

---

The software intangible asset was recognized as a result of the acquisition of Shenzhen Zhimeng. Amortization expense for intangible assets with finite useful lives was $805 and $80,550 for the years ended December 31, 2025 and September 30, 2025, respectively.

**4.7 DIGITAL ASSETS**

The Company's digital assets consist solely of Bitcoin. Digital assets are measured at fair value, with changes in fair value recognized in earnings for each reporting period. As of December 31, 2025, the company held 730 bitcoins, with a total value of $63,978,821.

**4.8 ACCOUNTS PAYABLE AND ACCRUED EXPENSES** 

Accounts payable and accrued expenses as of December 31, 2025 and September 30, 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2025** | **September 30, <br> 2025** |
| Accounts payable | $1788527 | $429322 |
| Accrued expenses | 1076224 | 1034822 |
| **Total** | **2864751** | **1464144** |

---

**4.9 SHORT TERM LOANS**

As of December 31, 2025, the Company's short-term loans totaled $452,764, consisting of the following:

<u>(a) Loan due to Mr. Sooncha Kim</u>

An amount of $348,926 relates to a loan from Mr. Sooncha Kim, which is currently subject to ongoing litigation between the Company and Mr. Sooncha Kim. Repayment of this amount has been suspended pending the resolution of the litigation, and the ultimate repayment terms and timing, if any, will be determined based on the outcome of such proceedings.

<u>(b) Loan due to Social E-Commerce Co., Ltd.</u>

An amount of $103,838 represents a legacy liability incurred under previous management. This amount is contractually repayable on or before June 30, 2026. As of the date of these financial statements, no repayment has been made, and the balance remains outstanding.

Subsequent to December 31, 2025, no repayments have been made in respect of the above short-term loans. The balance due to Mr. Kim continues to be subject to ongoing litigation.

**4.10 CONVERTIBLE NOTES**

As of December 31, 2025 and September 30, 2025, the Company had outstanding unconverted convertible notes of approximately $Nil and $1,838,041, respectively.

For the three months ended December 31, 2025, $1,838,041 worth of convertible notes were converted into the Company's Common Stock.

*(a) Non-related party convertible notes*

---

| | | |
|:---|:---|:---|
|  | **December 31, <br> 2025** | **September 30, <br> 2025** |
| Beginning balance | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $1063624 |
| Issuance of convertible notes |  | 10144186 |
| Fair value adjustment |  |  |
| Conversion to Common Stock | - | (11207810) |
| **Ending balance** | **-** | **-** |

---

All non-related party convertible notes outstanding as of September 30, 2024 were fully converted into shares of the Company's Common Stock on October 31, 2024.

*(b) Related party convertible notes*

---

| | | |
|:---|:---|:---|
|  | **December 31, <br> 2025** | **September 30, <br> 2025** |
| Beginning balance | $1838041 | $319220 |
| Issuance of convertible notes |  | 3693041 |
| Fair value adjustment |  |  |
| Conversion to Common Stock | (1838041) | (2174220) |
| **Ending balance** | **-** | **1838041** |

---

<u>Key issuance and conversion events</u>

(1) **August 20, 2024** – The Company issued convertible notes with an aggregate principal amount of $1,300,000, of which $1,000,000 was subscribed by non-related parties and $300,000 by a related party. As of September 30, 2024, the Company recorded a fair value adjustment of $82,844 related to these notes.

**October 31, 2024** – All holders of the August 2024 convertible notes elected to convert their notes into an aggregate of 1,396,813 shares of Common Stock. The shares were registered pursuant to the Company's Form S-1 filed on November 29, 2024.

(2) **December 12, 2024** – The Company issued convertible notes with an aggregate principal amount of $10,000,000, of which $8,145,000 was subscribed by non-related parties and $1,855,000 by a related party.

**February 10, 2025** – The Company obtained shareholder approval for the issuance of shares underlying the notes and warrants.

**March 18, 2025** – the investors submitted their respective conversion notices, upon which the Company issued 19,457,618 shares of Common Stock to the investors.

(3) **August 21, 2025** – The Company entered into a convertible bond purchase agreement with certain non-U.S. investors to issue convertible notes with an aggregate principal amount of $4,000,000, at a conversion price of $0.24 per shares, subject to adjustment in accordance with the Notes.

During the year ended September 30, 2025, the non-related parties notes with a carrying value of $1,999,962 were converted into 8,333,333 shares of Common Stock.

**October 30, 2025** – The remaining related party notes of 8,333,333 shares were issued subsequent to year-end and are disclosed as a subsequent event.

The convertible notes were measured at fair value, with changes in fair value recognized in fair value variation in the consolidated statements of operations.

**4.11 OTHER CURRENT LIABILITIES**

As of December 31, 2025 and September 30, 2025, other current liabilities amounted to $3,941,470 and $22,250,590, respectively.

Other current liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2025** | **September 30, <br> 2025** |
| Advances received for equity subscriptions<sup>(1)</sup> | $159657 | $18134657 |
| Provision for liabilities related to directors' litigation<sup>(2)</sup> | 222062 | 222062 |
| Professional service fees payable – Bitcoin transaction<sup>(3)</sup> | 3333579 | 3663269 |
| Others | 226172 | 230602 |
| **Total** | **3941470** | **22250590** |

---

*(1)* *Advances received for equity subscriptions* 

Advances received for equity subscriptions include $159,657 relating to a share subscription by Mr. Kim, and $17,975,000 representing subscription funds received in connection with Bitcoin-related investments.

The issuance of shares relating to Mr. Kim's equity subscription has been placed on hold due to ongoing litigation between Mr. Kim and the Company. Management intends to resolve the equity subscription upon conclusion of the legal proceedings.

With respect to the Bitcoin-related equity subscriptions, on September 25, 2025, the Company's board of directors approved an increase in the authorized number of the Common Stock from 200,000,000 to 600,000,000 shares. In October 2025, the Company amended its Articles of Incorporation to effect the increase. Following the amendment, 71,900,000 shares were issued and recorded as outstanding in the Company's shareholder register.

*(2)* *Provision for liabilities related to directors' litigation* 

The provision for liabilities related to directors' litigation of $222,062 represents management's estimate of costs associated with ongoing legal proceedings involving certain directors as of September 30, 2025.

*(3)* *Professional service fees payable – Bitcoin transaction* 

The professional service fees payable of $3,663,269 relate to a financial advisory services agreement executed on July 1, 2025, between the Company and Sunflower Tech Limited, in connection with a Bitcoin-related asset transaction with a total transaction value of $55.0 million. Under the agreement, the advisory fee is calculated at 10% of the transaction value, amounting to $5.5 million. As of December 31, 2025 and September 30, 2025, the remaining payable balances of the company were $3,333,579 and $3,663,269 respectively.

**4.12 TAX PAYABLE**

 

As of December 31, 2025 and September 30, 2025, taxes payable amounted to $2,394,591 and $1,314,686, respectively.

 

---

| | | |
|:---|:---|:---|
|  | **December 31, <br> 2025** | **September 30, <br> 2025** |
| VAT payable | $2391483 | $1311578 |
| Income tax payable | 3108 | 3108 |
| **Total** | **2394591** | **1314686** |

---

**4.13 OPERATING EXPENSES**

For the three months ended December 31, 2025, the operating expenses were $2,046,352. This mainly included personnel costs of $1,271,874, sales and marketing expenses of $201,219, depreciation and amortization of $1,073, professional fees (including legal, audit, and consulting services) of $490,206, travel expenses of $27,294, office expenses of $33,890, and other operating expenses of $20,796.

For the three months ended December 31, 2024, the operating expenses were $1,517,758. This mainly included personnel costs of $617,824, sales and marketing expenses of $104,403, depreciation and amortization of $7,771, professional services such as lawyers, auditors and consultants of $642,125, travel expenses of $35,084, office expenses of $73,585 and other expenses of $36,966.

**4.14 OTHER INCOME**

For the three months ended December 31, 2025, other income was $74,115, primarily arising from the consulting services provided by the Company.

For the three months ended December 31, 2024, the other income was $9,047. It is mainly because of the write-off other payables.

**4.15 OTHER EXPENSES**

For the three months ended December 31, 2025, other expense was $125,150, primarily attributable to the cost expenditures corresponding to other income, the company's financial expenses, and other factors.

For the three months ended December 31, 2024, other expense totaled $43,017, primarily included write off of deferred financing costs and sublease expense.

**5. GEOGRAPHIC CONCENTRATIONS**

The Company is organized based on fundamentally three business segments although it does sell its products on a world-wide basis. The Company is organized in two geographical segments. The Company jointly produces and sells its products in North America and China. Information about the Company's geographic operations for the three months ended December 31, 2025, and 2024 are as follows:

Geographic Concentration

---

| | | |
|:---|:---|:---|
| **Net Revenue:** | **Three months ended<br> December 31, 2025** | **Three months ended<br> December 31, 2024** |
| North America | $- | $- |
| P.R.C | 15768796 | 22853 |
|  | **15768796** | **22853** |

---

---

| | | |
|:---|:---|:---|
| **Property and equipment, net:** | **Three months ended<br> December 31, 2025** | **Three months ended<br> December 31, 2024** |
| North America | $- | $- |
| P.R.C | 1988 | 1997 |
|  | **1988** | **1997** |

---

**6. SEGMENT INFORMATION**

FASB ASC Topic 280, "Segment Reporting" ("ASC 280") establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the chief operating decision maker ("CODM"), or group, in deciding how to allocate resources and assess performance.

The Company's CODM has been identified as the Chief Financial Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, Management derived reportable segments based on business lines

As of December 31, 2025, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series and others.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Business Line** | **Business Line** | **Business Line** | **Others** | |
|  | **Homology of Medicine and Food**<br>**Series** | **Computing Power Product**<br>**Series** | **Maca Product**<br>**Series** | **Unallocated Headquarter**<br>**Costs** |<br>**Total** |
| Revenues, net | $1426832 | $2360373 | $11981591 | $- | $15768796 |
| Cost of revenue | (1408560) | (2289534) | (11981591) | - | (15679685) |
| **Gross profit** | **18272** | **70839** | **-** |  | **89111** |
| Operating expenses | (122596) | (256436) | - | (1667320) | (2046352) |
| **Loss from operations** | **(104324)** | **(185597)** | **-** | **(1667320)** | **(1957241)** |
| Fair value variation |  |  |  | (17502596) | (17502596) |
| Other income | 74115 |  |  |  | 74115 |
| Other expense | (117049) | (245) | - | (7856) | (125150) |
| **Segment Loss** | $**(147258)** | **(185842)** | **-** | **(19177772)** | **(19510872)** |

---

**7. RELATED PARTY BALANCES AND TRANSACTIONS**

As of December 31, 2025, the Company had the following major related party transactions:

---

| | |
|:---|:---|
| **Name of related parties** | **Relationship with Company** |
| Wanhai Liu | Shareholder of Xilin Online (Beijing) E-commerce Co., Ltd |
| Tianyong Lv | Manager of Xilin Online (Beijing) E-commerce Co., Ltd |
| Shengqing Li | Manager of Shenzhen Zhimeng Qiyang Technology Co., Ltd. |
| Hongfang Xie | Shareholder of Shanghai Huomao Cultural Development Co., Ltd. |
| Wenlong Tong | President of CIMG Inc. |
| Wenwen Yu | Director of Wewin Technology LLC |
| Yujie Liu | The shareholders of CIMG |
| Yanli Hou | Director of CIMG Inc. |

---

*(a) Significant transactions with related parties*

---

| | | |
|:---|:---|:---|
| **Name of related parties** | **Related party transactions** | **December 31, <br> 2025** |
| Wanhai Liu | Loan advanced to Xilin Online (Beijing) E-commerce Co., Ltd | $12698 |
| Tianyong Lv | Loan advanced to Xilin Online (Beijing) E-commerce Co., Ltd | 12940 |
| Shengqing Li | Loan advanced to Shenzhen Zhimeng Qiyang Technology Co., Ltd. | 191329 |
| Hongfang Xie | Loan advanced to Shanghai Huomao Cultural Development Co., Ltd. | 5037 |
| Hongfang Xie | Loan advanced to Guizhou Zhutai Huomao Liquor Industry Co., Ltd. | 117487 |
| Yujie Liu | Loan advanced to Zhongyan Shangyue Technology Co., Ltd | 213198 |
| Yujie Liu | Loan advanced to Henan Zhongyan Shangyue Technology Co., Ltd | 52730 |
| Wenwen Yu | Loan advanced to CIMG Inc | 7500 |
| Wenlong Tong | Loan advanced from Zhongyan Shangyue Technology Co., Ltd | (15911) |
| Wenwen Yu | Loan advanced from Wewin Technology LLC. | (150762) |
| Yanli Hou | Loan advanced from Zhongyan Shangyue Technology Co., Ltd | (42041) |

---

**<u>Nature of Related Party Transactions</u>**

As of December 31, 2025, the Company and its subsidiaries entered into certain transactions with related parties in the ordinary course of business. These transactions primarily consisted of advances made by related parties to settle operating and administrative expenses on behalf of the Company's subsidiaries, as well as financing arrangements entered into with related parties.

Except as otherwise disclosed, all advances from or to related parties were unsecured, non-interest bearing, and had no fixed repayment terms. Management believes that the terms of these transactions are not materially different from those that could have been obtained from independent third parties under similar circumstances.

*(b) Balances with related parties*

---

| | |
|:---|:---|
|  | **December 31, <br>2025** |
| Wenlong Tong | $15911 |
| Wenwen Yu | 150762 |
| Yanli Hou | 42041 |
| **Total amounts due from related parties** | **208714** |
| Wanhai Liu | $12698 |
| Tianyong Lv | 12940 |
| Shengqing Li | 191329 |
| Hongfang Xie | 122544 |
| Wenwen Yu | 7500 |
| Yujie Liu | 265928 |
| **Total amounts due to related parties** | **612939** |

---

The amounts due from and due to related parties primarily arose from payments made on behalf of the Company or its subsidiaries for operating, administrative, and legal expenses, as well as advances and settlements in the ordinary course of business. Such balances are recorded at their original amounts, which approximate fair value due to their short-term nature.

As of the date of issuance of these financial statements, management does not expect any material credit losses in respect of amounts due from related parties.

**8. ISSUANCE OF EQUITY SECURITIES**

On December 5, 2025, the Company effected a 1-for-20 reverse stock split (the "Reverse Stock Split") of its issued and outstanding shares of Common Stock, par value $0.00001 per share. This reverse stock split has reduced the number of shares of Common Stock as of September 30, 2025 from 196,514,084 shares to 9,825,704 shares, and corresponding retroactive adjustments have been made to all the data for the listed period.

(1) For the three months ended December 31, 2025, the Common Stock issued for cash was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date** | **Transaction type** | **Description** | **Shares issued** | **Cash/consideration ($)** |
| August 21, 2025 | Convertible Note Purchase Agreement<br>(From 8-K filed August 26, 2025, Form 8-K filed on November 12, 2025) | On August 21, 2025, the Company entered into a $4,000,000 convertible bond purchase agreement with certain non-U.S. investors. The notes are convertible into shares of the Company's Common Stock at a conversion price of $0.24 per share.<br>On September 9, 2025, the Company issued 8,333,333 shares. <br>On October 30, 2025, the Company issued the remaining 8,333,333 shares. | 8333333 | $2000000 |
| **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **8333333** | **2000000** |
| **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **416667** | **13382030** |

---

(2) For the three months ended December 31, 2025, the issuance of Common Stock due to the Common Stock compensation was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date** | **Transaction type** | **Description** | **Shares issued** | **Cash/consideration ($)** |
| November 21, 2025. | 2025 Equity Incentive Plan <br>(From S-8 filed November 21, 2025) | This Registration Statement on Form S-8 (this "Registration Statement") is filed by CIMG Inc., a Nevada corporation (the "Registrant" or "Company"), to register (i) 7,279,400 of the Registrant's shares of Common Stock, par value $0.00001 per share (the "Common Stock"), issuable under the Company's 2025 Equity Incentive Plan (the "2025 Plan"), and (ii) 38,000,000 shares of Common Stock, issuable under the Registrant's 2026 Equity Incentive Plan (the "2026 Plan"). | 7279400 | 1163976 |
| **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **7279400** | **1163976** |
| **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **363970** | **1163976** |

---

(3) For the three months ended December 31, 2025, the issuance of Common Stock due to the private placement was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date** | **Transaction type** | **Description** | **Shares issued** | **Cash/consideration ($)** |
| August 25, 2025\* | Securities Purchase Agreement<br>(Form 8-K filed on August 27, 2025, Form 8-K/A filed on September 2, 2025) | On August 25, 2025, the Company entered into a securities purchase agreement with certain non-U.S. investors for total consideration of $55,000,000, payable in Bitcoin, at a purchase price of $0.25 per share. The agreement provides for the issuance of up to 220,000,000 shares of Common Stock through a private placement, of which 148,100,000 shares, representing $37,025,000 of consideration, were issued during the period.<br>On September 2, 2025, the Company issued 148,100,000 shares of Common Stock to certain non-U.S. investors. <br>On October 29, 2025, the Company issued the remaining 71,900,000 shares. | 71900000 | 16177500 |
| **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **Total (Pre-Reverse Stock Split)** | **71900000** | **16177500** |
| **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **Total (Post-Reverse Stock Split)** | **3595000** | **16177500** |

---

**Restricted Stock Awards**

For the three months ended December 31, 2025, the Company did not grant any restricted stock awards.

**Grants to Independent Directors**

No restricted stock awards were granted to the Company's independent board members during the three months ended December 31, 2025.

**Forfeiture of Restricted Shares**

For the three months ended December 31, 2025, no restricted stock awards were forfeited.

**Common Stock Issued for Services**

The Company did not issue any shares of Common Stock in exchange for services during the three months ended December 31, 2025.

**Exercise of Stock Options**

No stock options were exercised during the three months ended December 31, 2025.

**9. STOCK OPTIONS AND WARRANTS**

<u>STOCK OPTIONS</u>

During the three months ended December 31, 2025 and 2024, the Company granted no new stock options.

During the same period, 1,022 stock options were forfeited or expired as a result of employee terminations, expiration of option terms, or performance conditions not being met.

<u>WARRANTS</u>

The Company has issued warrants to purchase shares of Common Stock in connection with equity financings and convertible note transactions. The following disclosures summarize warrant issuances, exercises, and outstanding balances for the periods presented.

All share and per-share amounts, including exercise prices and number of warrants, have been retroactively adjusted to reflect the Reverse Stock Split on December 5, 2025.

***Significant warrant transactions***

On April 27, 2024, the Company entered into a convertible note and warrant purchase agreement with certain investors, pursuant to which the Company issued warrants to purchase shares of Common Stock. On October 18, 2024, holders of such warrants exercised a portion of the warrants on a cashless basis, resulting in the issuance of 55,973 shares of Common Stock. No cash proceeds were received in connection with the cashless exercise.

On January 16, 2025, and January 17, 2025, the Company issued an aggregate of 1,282,051 warrants to purchase Common Stock at an exercise price of $7.80 per share. These warrants had a contractual term of two years and were fully exercised on October 29, 2025.

The following table summarizes warrant activity for the three months ended December 31, 2025:

*(Retroactively adjusted for Reverse Stock Split)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of <br>Shares <br>Issuable** | **Weighted <br>Average <br>Exercise <br>Price** | **Weighted <br>Average <br>Remaining <br>Life (years)** | **Aggregate <br>Intrinsic <br>Value** |
| Outstanding on September 30, 2025 | 1289937 | $2253.40 | 2.42 | $- |
| Issued |  |  |  |  |
| Exercised | 1282051 | 7.80 |  |  |
| Expired |  |  |  |  |
| Outstanding on December 31, 2025 | 7886 | $26.19 | 1.29 |  |
| Exercisable on December 31, 2025 | 7886 | $26.19 | 1.29 | $- |

---

**Reverse Stock Split**

On December 2, 2025, the Company filed a Certificate of Change to its Articles of Incorporation with the Secretary of State of the State of Nevada to effect a 1-for-20 reverse stock split of its issued and outstanding Common Stock, which became effective on December 5, 2025. All share and per-share data included in these financial statements have been retroactively adjusted to reflect the Reverse Stock Split.

**10. CONTINGENCIES**

<u>The Kim Litigation</u>

On October 3, 2024, Mr. Sooncha Kim filed a complaint against the Company in the Southern District of New York, (Case No. 1:24-cv-7485) (the "Complaint"). The Complaint alleges that the Company breached a Convertible Note and Warrant Purchase Agreement, dated June 6, 2024, between the Company and Mr. Kim, by, among other things, failing to deliver the registration rights agreement, excluding Mr. Kim from the S-1 registration statement, delaying conversion of Mr. Kim's notes, undertaking steps to dilute Mr. Kim's shares, failing to honor Mr. Kim's 50% participation right in any subsequent financing and failing to appoint a designated director, as set forth in the parties' agreement. Mr. Kim seeks specific performance of the Convertible Note and Warrant Purchase Agreement, and monetary damages in the amount of $1,041,216, plus applicable interest. The Company filed its answer to the Complaint on December 3, 2024. On January 7, 2025, Mr. Kim filed a motion seeking a preliminary injunction against the Company (the "Motion"). The Company opposed the Motion on January 22, 2025, and on February 13, 2025, the Court denied Mr. Kim's Motion. As of December 31, 2025, discovery in the case is ongoing, and no trial date has been set.

<u>The Ex-Directors Lawsuit</u>

On March 10, 2025, the following former directors of the Company, Kevin J. Connor, Chris J. Jones, Nobuki Kurita, and David Robson (collectively, the "Ex-Directors"), filed a complaint against the Company in the Superior Court of California, County of San Diego (Case No. 25CU012922N) (the "Complaint"). The Complaint alleges the Company failed to pay directors' fees and expenses from the last quarter the fiscal year ended September 30, 2023 through the first two quarters of the fiscal year ended September 30, 2024, and is claiming breach of contract, quantum meruit, unjust enrichment, promissory estoppel, breach of the implied covenant of good faith and fair dealing, and unfair business practices. On August 22, 2025, a judgment by default was entered against the Company in the amount of $58,920.34. Counsel for Plaintiffs/Judgment Creditors, Kevin J. Conner, J. Chris Jones, Nobuki Kurita, and David Robson (collectively, "Plaintiffs") subsequently filed a motion with the court to amend the total amount of the judgment. On November 21, 2025, the Court entered an order amending the judgment nunc pro tunc, increasing the aggregate awards to all Plaintiffs to $222,062.28, including the prejudgment interest and costs. As the underlying condition existed as of the reporting date, this event represents an adjusting subsequent event, and the related liability has been recognized in Note 4.15 to the financial statements.

**11. SUBSEQUENT EVENTS**

**Convertible Notes**

On February 11, 2026, the Company entered into a convertible note and warrant purchase agreement with certain non-U.S. investors providing for the private placement of convertible promissory notes in the aggregate principal amount of $5,000,000 and warrants to purchase the Company's shares of Common Stock in reliance on the registration exemptions of Regulation S . The Notes are issuable in two tranches, consisting of (i) an initial tranche in the aggregate principal amount of $1,600,000 and (ii) a second tranche in the aggregate principal amount of $3,400,000. The Notes bear interest at an annual rate of 7% and have a maturity date of August 12, 2027.

On February 13, 2026, the Company completed the initial closing and issued Notes in the aggregate principal amount of $1,600,000 to the Investors.

**Changes in Registrant's Certifying Accountant.**

On February 18, 2026, the Audit Committee of the Board of Directors of CIMG Inc. approved the dismissal of Assentsure PAC as the Company's independent registered public accounting firm, effective as of such date.

On February 18, 2026, the Audit Committee approved the engagement of ST & Partners PLT as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2026.

**Legal Proceedings**

<u>The Kim Litigation</u>

On October 3, 2024, Mr. Sooncha Kim filed a complaint against the Company in the Southern District of New York, (Case No. 1:24-cv-7485) (the "Complaint"). The Complaint alleges that the Company breached a Convertible Note and Warrant Purchase Agreement, dated June 6, 2024, between the Company and Mr. Kim, by, among other things, failing to deliver the registration rights agreement, excluding Mr. Kim from the S-1 registration statement, delaying conversion of Mr. Kim's notes, undertaking steps to dilute Mr. Kim's shares, failing to honor Mr. Kim's 50% participation right in any subsequent financing and failing to appoint a designated director, as set forth in the parties' agreement. Mr. Kim seeks specific performance of the Convertible Note and Warrant Purchase Agreement, and monetary damages in the amount of $1,041,216, plus applicable interest. The Company filed its answer to the Complaint on December 3, 2024. On January 7, 2025, Mr. Kim filed a motion seeking a preliminary injunction against the Company (the "Motion"). The Company opposed the Motion on January 22, 2025, and on February 13, 2025, the Court denied Mr. Kim's Motion. As of December 31, 2025, discovery in the case is ongoing, and no trial date has been set.

<u>The Ex-Directors Lawsuit</u>

On March 10, 2025, the following former directors of the Company, Kevin J. Connor, Chris J. Jones, Nobuki Kurita, and David Robson (collectively, the "Ex-Directors"), filed a complaint against the Company in the Superior Court of California, County of San Diego (Case No. 25CU012922N) (the "Complaint"). The Complaint alleges the Company failed to pay directors' fees and expenses from the last quarter the fiscal year ended September 30, 2023 through the first two quarters of the fiscal year ended September 30, 2024, and is claiming breach of contract, quantum meruit, unjust enrichment, promissory estoppel, breach of the implied covenant of good faith and fair dealing, and unfair business practices. On August 22, 2025, a judgment by default was entered against the Company in the amount of $58,920.34. Counsel for Plaintiffs/Judgment Creditors, Kevin J. Conner, J. Chris Jones, Nobuki Kurita, and David Robson (collectively, "Plaintiffs") subsequently filed a motion with the court to amend the total amount of the judgment. On November 21, 2025, the Court entered an order amending the judgment nunc pro tunc, increasing the aggregate awards to all Plaintiffs to $222,062.28, including the prejudgment interest and costs. As the underlying condition existed as of the reporting date, this event represents an adjusting subsequent event, and the related liability has been recognized in Note 4.15 to the financial statements.

<u>New Subsidiaries</u>

On February 4, 2026, Beijing Xin Miao Shi Dai Technology Development Co., Ltd. established a wholly-owned subsidiary, Foshan Dingyue Technology Co., Ltd.

On February 5, 2026, Zhongyan Shangyue Technology Co., Ltd. established a wholly-owned subsidiary, Foshan Lintai Technology Co., Ltd.

**Item 2. Quantitative and Qualitative Disclosures About Market Risk.**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

**Item 3. Controls and Procedures**

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by our Company is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is collected and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for our Company. In designing and evaluating our disclosure controls and procedures, management recognizes that no matter how well conceived and operated, disclosure controls and procedures can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Our management assessed the effectiveness of the Company's internal control over financial reporting as of the end of the period covered by this Report based on the criteria for effective internal control described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organization of the Treadway Commission. Based on this assessment, our management has concluded that the Company's internal control over financial reporting was not effective as of December 31, 2025.

As we are a non-accelerated filer, our independent registered public accounting firm is not required to issue an attestation report on our internal control over financial reporting.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

Refer to "Note 10. Contingencies" and "Note 11. Subsequent Events—Legal Proceedings" in our Consolidated Financial Statements included in this Report.

**Item 1A. RISK FACTORS**

In addition to the other information set forth in this Report, you should carefully consider the risk factors discussed in "Item 1A-Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on February 13, 2026, which could affect our business, financial condition, or operating results. The risks described in our annual or quarterly reports filed with the SEC are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, or operating results. For the three months ended December 31, 2025, we were not aware of any new and additional risk factors that were not previously disclosed.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

(a) Subsequent to the quarter ended December 31, 2025, the Company completed the following unregistered issuances of its equity securities:

On February 11, 2026, the Company entered into a convertible note and warrant purchase agreement (the "February Purchase Agreement") with certain non-U.S. investors (the "February Investors"), providing for the private placement of convertible promissory notes in the aggregate principal amount of $5,000,000 (the "February Notes") and warrants to purchase the Company's shares of Common Stock (the "February Warrants") in reliance on Regulation S as an exemption to the registration (the "February Transaction"). The Notes are issuable in two tranches, consisting of (i) an initial tranche in the aggregate principal amount of $1,600,000 and (ii) a second tranche in the aggregate principal amount of $3,400,000. The Notes issued in the first tranche bear interest at an annual rate of 7% and have a maturity date of August 12, 2027. On February 13, 2026, the Company completed the initial closing and issued February Notes in the aggregate principal amount of $1,600,000 to the February Investors. As of the date of this Report, none of the February Warrants has been exercised, none of the February Notes has been converted, and no shares of Common Stock have been issued pursuant to the February Transaction.

(b) None.

(c) None.

**Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 4. MINE SAFETY DISCLOSURES**

Not applicable.

**Item 5. OTHER INFORMATION**

During the three months ended December 31, 2025, none of the Company's directors or officers, as defined in Section 16 of the Securities Exchange Act of 1934, adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined under Item 408(a) of Regulation S-K.

**Item 6. EXHIBITS**

---

| | |
|:---|:---|
| Exhibit<br> Number | Description |
| 3.1 | [Articles of Incorporation of the Company, dated July 15, 2011 (incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K filed on December 23, 2022, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315222036487/ex3-1.htm) |
| 3.2 | [Certificate of Amendment to Articles of Incorporation of the Company, dated May 6, 2013 (incorporated by reference to Exhibit 3.01(b) to the Company's Current Report on Form 8-K filed on April 25, 2013, SEC File Number 333-176684).](https://www.sec.gov/Archives/edgar/data/1527613/000129460613000103/exhibit301b.htm) |
| 3.3 | [Certificate of Amendment to Articles of Incorporation of the Company, dated October 28, 2019 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on October 28, 2019, SEC File Number 000-55157).](https://www.sec.gov/Archives/edgar/data/1527613/000137647419000260/nz_ex3z1.htm) |

---

---

| | |
|:---|:---|
| 3.4 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation filed on October 22, 2024. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on October 28, 2024, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315224042696/ex3-1.htm) |
| 3.5 | [Certificate of Amendment to the Articles of Incorporation of the Company, dated October 28, 2025 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on October 31, 2025, SEC File No. 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315225020377/ex3-1.htm) |
| 3.6 | [Certificate of Change to the Articles of Incorporation of the Company, dated December 2, 2025 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 5, 2025, SEC File No. 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315225026431/ex3-1.htm) |
| 3.7 | [Third Amended and Restated Bylaws of the Company, effective March 17, 2022 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on March 23, 2022, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315222007542/ex3-1.htm) |
| 4.1 | [Description of Securities (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed on December 23, 2022, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315222036487/ex4-1.htm) |
| 4.2 | [Series A Warrant Agent Agreement (including the terms of the Series A Warrant) (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315221006585/ex4-1.htm) |
| 4.3 | [Series B Warrant Agent Agreement (including the terms of the Series B Warrant) (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on March 23, 2021, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315221006585/ex4-2.htm) |
| 4.4 | [Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on April 15, 2022, SEC File Number 001-39338).](https://www.sec.gov/Archives/edgar/data/1527613/000149315222010098/ex4-1.htm) |
| 4.5 | [Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on May 2, 2024, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315224017565/ex4-1.htm) |
| 4.6 | [Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on December 17, 2024, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315224050439/ex10-3.htm) |
| 4.7 | [Form of Warrant (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315226007207/ex10-3.htm) |
| 10.1 | [CIMG Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315226006817/ex10-8.htm) |
| 10.2 | [CIMG Inc. 2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company's Annual Report on Form 10-K filed on February 13, 2026, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315226006817/ex10-9.htm) |
| 10.3 | [Purchase Agreement, dated February 11, 2026, by and among the Company and the Investors party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315226007207/ex10-1.htm) |
| 10.4 | [Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on February 17, 2026, SEC File Number 001-39338)](https://www.sec.gov/Archives/edgar/data/1527613/000149315226007207/ex10-2.htm) |
| 31.1\* | [Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm) |
| 31.2\* | [Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm) |
| 32.2\*\* | [Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm) |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

**\*** Filed herewith.

**\*\*** Furnished herewith. This exhibit will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | CIMG INC. | CIMG INC. |
| Date: March 5, 2026 | By: | */s/ Jiangshuang Wang* |
|  |  | Jianshuang Wang |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |
|  | By: | */s/ Feng Tian* |
|  |  | Feng Tian |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer and Principal Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jianshuang Wang, certify that:

1. I have reviewed this report on Form 10-Q of CIMG Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 5, 2026

---

| |
|:---|
| */s/ Jianshuang Wang* |
| Jianshuang Wang |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Feng Tian, certify that:

1. I have reviewed this report on Form 10-Q of CIMG Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 5, 2026

---

| |
|:---|
| */s/ Feng Tian* |
| Feng Tian |
| Chief Financial Officer |
| (Principal Accounting and Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies, in her capacity as an officer of CIMG Inc. (the "Company"), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Quarterly Report of the Company on Form 10-Q for the three months ended December 31, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 5, 2026

---

| |
|:---|
| */s/ Jianshuang Wang* |
| Jianshuang Wang |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies, in his capacity as an officer of CIMG Inc. (the "Company"), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Quarterly Report of the Company on Form 10-Q for the three months ended December 31, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 5, 2026

---

| |
|:---|
| */s/ Feng Tian* |
| Feng Tian |
| Chief Financial Officer |
| (Principal Accounting and Financial Officer) |

---

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.